Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors
机构:[1]Department of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China.临床科室肿瘤内科河北医科大学第四医院[2]Inspection Department, Shijiazhuang Institue for Food and Drug Control, Shijiazhuang, Hebei, China.
第一作者机构:[1]Department of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
通讯作者:
通讯机构:[1]Department of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
推荐引用方式(GB/T 7714):
Liu Jiayin,Li Dan,Han Jing,et al.Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors[J].FRONTIERS IN ONCOLOGY.2023,13:doi:10.3389/fonc.2023.1091669.
APA:
Liu Jiayin,Li Dan,Han Jing,Zhang Yin,Zhang Xue...&Wang Yudong.(2023).Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors.FRONTIERS IN ONCOLOGY,13,
MLA:
Liu Jiayin,et al."Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors".FRONTIERS IN ONCOLOGY 13.(2023)